Miriam Fuchs
Senior Associate
Miriam Fuchs
Senior Associate
Miriam consistently delivers exceptional client service, demonstrating attentiveness, clear communication and a proactive approach to meeting client needs.
– Chambers Europe
About Miriam Fuchs
Miriam Fuchs is a senior member of the Corporate/M&A team with a particular focus on Life Sciences & Healthcare. She has extensive experience advising on complex commercial and regulatory matters across the full spectrum of pharmaceutical and medtech products. Miriam regularly advises her clients on various contractual structures, regulatory and compliance activities, regulatory proceedings, investigations, internal compliance process reviews, and dispute matters.
Beyond her life sciences practice, Miriam advises international clients on a broad range of commercial and regulatory matters, including corporate investigations, compliance, internal audits, competition and antitrust matters, M&A transactions, and restructurings. In addition to providing ongoing legal support and project-based engagements, Miriam regularly conducts trainings for her clients and gives presentations to professional audiences on the topics above. Miriam has experience representing clients in the internal handling of various compliance infringements or deficiencies, as well as in proceedings before regulatory bodies and authorities.
Prior to joining Wolf Theiss, Miriam co-developed and co-led the Hungarian Life Sciences practice of an international law firm which achieved international recognition, with a special focus on health care regulatory matters.
Education
Eötvös Loránd University, Budapest (J.D.), 2011
Languages
Hungarian, English
Related insights
GVH guidance on health and nutrition claims in food and dietary supplement advertising
On 7 April 2026, the Hungarian Competition Authority (GVH) published a guidance booklet on the rules governing health, nut...
Read more
Hungarian pharmaceutical authority imposes fines for non-compliant promotional activity
On 17 March 2026, the Hungarian National Public Health and Pharmaceutical Authority (NNGYK) announced they have imposed a ...
Read more
Hungarian Competition Authority launches two competition proceedings in the OTC pharmaceutical market
On 12 February 2026, the Hungarian Competition Authority (GVH) announced the launch of two separate competition supervisio...
Read more
Wolf Theiss advises on the acquisition of three FLAGA-branded liquid gas businesses in Hungary, the Czech Republic and Slovakia
Budapest, 9 February 2026 – Wolf Theiss advised DCC plc, the leading international energy sales group, on the acquisitio...
Read more
Life Sciences Bulletin: Hungarian Medicines Authority resumes investigations into pharma promotions
The Hungarian National Centre for Public Health and Pharmacy (NNGYK or the Authority) has issued its first decision in mor...
Read more
American Industrial Partners to acquire AGCO Corporation’s Grain & Protein division with M&A and regulatory support from Wolf Theiss
Vienna, Prague, Budapest, 7 August 2024 – Wolf Theiss advises American Industrial Partners (AIP), a global industrials i...
Read more
Life Sciences Bulletin: New public foundation to oversee exceptional drug funding in Hungary as of 2025
Commencing in 2025, the Batthyány-Strattmann László Foundation will assume the responsibility of managing applications ...
Read more
Life Sciences Bulletin: CJEU ruling on the online sale of OTC medicines may impact Hungarian market
The recent judgement of the Court of Justice of the European Union (“CJEU”) on the sale of over-the-counter (O...
Read more
Hungarian legislation reform related to centralised procurement for institutional pharmacies
The governmental decree published on 22 February (No. 33/2024 (II. 22.)) sets forth the establishment of a new project com...
Read more